{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:20:43Z","timestamp":1759033243604},"reference-count":116,"publisher":"Public Library of Science (PLoS)","issue":"5","content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1000434","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T20:31:14Z","timestamp":1304454674000},"page":"e1000434","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature"],"prefix":"10.1371","volume":"8","author":[{"given":"Alexander C.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas Z.","family":"Rosenlicht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon N.","family":"Jureidini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen I.","family":"Spielmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1034\/j.1399-5618.2000.20307.x","article-title":"Onset of action of antipsychotics in the treatment of mania.","volume":"2","author":"M Tohen","year":"2000","journal-title":"Bipolar Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2006.08.017","article-title":"Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.","volume":"99","author":"M Wolfsperger","year":"2007","journal-title":"J Affect Disord"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1371\/journal.pmed.0030185","article-title":"The latest mania: selling bipolar disorder.","volume":"3","author":"D Healy","year":"2006","journal-title":"PLoS Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1399-5618.2009.00711.x","article-title":"Medicating mood with maintenance in mind: bipolar depression pharmacotherapy.","volume":"11","author":"GS Malhi","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11673-010-9208-8","article-title":"From evidence-based medicine to marketing-based medicine: evidence from internal industry documents.","volume":"7","author":"GI Spielmans","year":"2010","journal-title":"J Bioeth Inquiry"},{"key":"ref6","first-page":"1","article-title":"From mania to bipolar disorder.","author":"D Healy","year":"2010"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11533120-000000000-00000","article-title":"For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians.","volume":"24","author":"TL Mark","year":"2010","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1176\/ps.2008.59.10.1169","article-title":"Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004.","volume":"59","author":"C Depp","year":"2008","journal-title":"Psychiatr Serv"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.","volume":"48","author":"E Frank","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0924-9338(01)00587-9","article-title":"Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues.","volume":"16","author":"JG Storosum","year":"2001","journal-title":"Eur Psychiatry"},{"key":"ref11","first-page":"16","article-title":"Strategies for preventing the recurrence of bipolar disorder.","volume":"65","author":"SN Ghaemi","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"ref12","article-title":"Relapse prevention in bipolar disorder: have any neuroleptics been shown to be \u2018mood stabilizers\u2019?","author":"FK Goodwin","year":"2011"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1097\/00004714-199604001-00005","article-title":"Bipolar mood disorder: practical strategies for acute and maintenance phase treatment.","volume":"16","author":"GS Sachs","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"ref14","first-page":"1","article-title":"The expert consensus guideline series: medication treatment of bipolar disorder 2000.","author":"GS Sachs","year":"2000"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4088\/JCP.v66n0710","article-title":"The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.","volume":"66","author":"T Suppes","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v67n0401","article-title":"Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.","volume":"67","author":"RH Perlis","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.","volume":"64","author":"H Scherk","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.31887\/DCNS.2008.10.2\/evieta","article-title":"Acute and long-term treatment of mania.","volume":"10","author":"E Vieta","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.ajp.161.1.3","article-title":"What is a \u201cmood stabilizer\u201d? An evidence-based response.","volume":"161","author":"MS Bauer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1399-5618.2001.030304.x","article-title":"On defining \u2018mood stabilizer\u2019.","volume":"3","author":"SN Ghaemi","year":"2001","journal-title":"Bipolar Disord"},{"key":"ref21","article-title":"Manic-depressive illness: bipolar disorders and recurrent depression.","author":"FK Goodwin","year":"2007"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).","volume":"166","author":"T Suppes","year":"2009","journal-title":"Am J Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(09)61828-6","article-title":"Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.","volume":"375","author":"JR Geddes","year":"2010","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/ps.2006.57.5.660","article-title":"Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants.","volume":"57","author":"SN Ghaemi","year":"2006","journal-title":"Psychiatr Serv"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1399-5618.2001.30401.x","article-title":"Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines.","volume":"3","author":"PZ Lim","year":"2001","journal-title":"Bipolar Disord"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1399-5618.2002.01223.x","article-title":"The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder.","volume":"4","author":"S Frangou","year":"2002","journal-title":"Bipolar Disord"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1176\/appi.ajp.159.6.1005","article-title":"Trends in the treatment of bipolar disorder by outpatient psychiatrists.","volume":"159","author":"C Blanco","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref28","first-page":"260","article-title":"Prescribing trends of antidepressants in bipolar depression.","volume":"56","author":"M Tohen","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"ref29","article-title":"Approval package for 21-436\/S-005 & S-008 & 21-713\/S-003.","year":"2005"},{"key":"ref30","article-title":"Top 15 U.S. pharmaceutical products by sales. IMS National Sales Perspectives(TM).","year":"2010"},{"key":"ref31","article-title":"Brands and strategies: atypical antipsychotics.","author":"ST Chow","year":"2008"},{"key":"ref32","article-title":"New Molecular Entity review follow-up: aripiprazole.","author":"I Diak","year":"2008"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/01.mlr.0000185731.71972.d4","article-title":"Physician decisions to discontinue long-term medications using a two-stage framework: the case of growth hormone therapy.","volume":"43","author":"L Cuttler","year":"2005","journal-title":"Med Care"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1377\/hlthaff.22.1.154","article-title":"Trends in U.S. health care spending, 2001.","volume":"22","author":"K Levit","year":"2003","journal-title":"Health Aff (Millwood)"},{"key":"ref35","article-title":"Clinical trials registry.","year":"2010"},{"key":"ref36","article-title":"The federal information manual.","author":"S Gidiere","year":"2006"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM200006013422206","article-title":"Coverage by the news media of the benefits and risks of medications.","volume":"342","author":"R Moynihan","year":"2000","journal-title":"N Engl J Med"},{"key":"ref38","article-title":"Statistical methods for rates and proportions. 2nd edition.","author":"J Fleiss","year":"1981"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","article-title":"A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.","volume":"67","author":"PE Keck Jr","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v68n1003","article-title":"Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.","volume":"68","author":"PE Keck Jr","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref41","article-title":"A multicenter, placebo-controlled, double-blind investigative extension trial of the safety and efficacy of aripiprazole in the treatment of patients with bipolar disorder experiencing a manic or mixed episode (NCT00606177).","year":"2010"},{"key":"ref42","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole monotherapy in the treatment of acutely manic patients with bipolar I disorder (CN138-135LT).","year":"2008"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2008.05.014","article-title":"Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.","volume":"112","author":"PE Keck","year":"2009","journal-title":"J Affect Disord"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1742-1241.2008.01735.x","article-title":"Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study.","volume":"62","author":"DJ Muzina","year":"2008","journal-title":"Int J Clin Pract"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.","volume":"160","author":"PE Keck Jr","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref46","article-title":"Statistical review and evaluation. Center for Drug Evaluation and Research approval package for 21-436\/S-005 & S-008 & 21-713\/S-003.","author":"K He","year":"2004"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archpsyc.60.4.392","article-title":"A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.","volume":"60","author":"CL Bowden","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.","volume":"163","author":"M Tohen","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4088\/JCP.v64n0906","article-title":"A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.","volume":"64","author":"JR Calabrese","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0006-3223(00)00909-4","article-title":"Historical perspectives and natural history of bipolar disorder.","volume":"48","author":"J Angst","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1399-5618.2009.00726.x","article-title":"The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders.","volume":"11","author":"M Tohen","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2010.00861.x","article-title":"From BALANCE to DSM-5: taking lithium seriously.","volume":"12","author":"SN Ghaemi","year":"2010","journal-title":"Bipolar Disord"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00004714-198109000-00003","article-title":"Methodological problems in studies of depressive disorder: utility of the discontinuation design.","volume":"1","author":"FM Quitkin","year":"1981","journal-title":"J Clin Psychopharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.1976.01770030051007","article-title":"Prophylaxis of affective disorders. Current status of knowledge.","volume":"33","author":"F Quitkin","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"ref55","article-title":"Clinical review. Center for Drug Evaluation and Research approval package for 21-436\/S-005 & S-008 & 21-713\/S-003.","author":"TA Prodruchny","year":"2004"},{"key":"ref56","first-page":"30","article-title":"Hippocratic psychopharmacology for bipolar disorder: an expert's opinion.","volume":"3","author":"SN Ghaemi","year":"2006","journal-title":"Psychiatry (Edgmont)"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1399-5618.2005.00206.x","article-title":"Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect.","volume":"7","author":"D Deshauer","year":"2005","journal-title":"Bipolar Disord"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1399-5618.2007.00490.x","article-title":"Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.","volume":"9","author":"LA Smith","year":"2007","journal-title":"Bipolar Disord"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1991.01810280029004","article-title":"Methodologic issues in maintenance therapy clinical trials.","volume":"48","author":"JB Greenhouse","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archpsyc.1990.01810200095016","article-title":"Unnecessary confusion about opposite findings in two studies of tricyclic treatment of bipolar illness.","volume":"47","author":"TA Wehr","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(00)00991-4","article-title":"Bipolar disorder therapeutics: maintenance treatment.","volume":"48","author":"GS Sachs","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/archpsyc.1990.01810200096017","article-title":"Unnecessary confusion about opposite findings in two studies of tricyclic treatment of bipolar illness. Reply.","volume":"47","author":"DR Shapiro","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1503\/cmaj.071068","article-title":"Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials.","volume":"178","author":"D Deshauer","year":"2008","journal-title":"CMAJ"},{"key":"ref64","article-title":"Antiepileptic drugs and suicidality.","author":"M Levenson","year":"2008"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"b2880","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.","volume":"339","author":"M Stone","year":"2009","journal-title":"BMJ"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"s157","DOI":"10.1192\/bjp.178.41.s157","article-title":"Evolving methodologies in bipolar disorder maintenance research.","volume":"Suppl 41","author":"JR Calabrese","year":"2001","journal-title":"Br J Psychiatry"},{"key":"ref67","first-page":"5","article-title":"Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder.","volume":"60","author":"JR Calabrese","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"ref68","first-page":"859","article-title":"Rapid recurrence of mania following lithium withdrawal.","volume":"15","author":"YD Lapierre","year":"1980","journal-title":"Biol Psychiatry"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0140-6736(88)92947-9","article-title":"Rapid recurrence of mania following abrupt discontinuation of lithium.","volume":"2","author":"AJ Mander","year":"1988","journal-title":"Lancet"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00045391-199607000-00004","article-title":"Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research.","volume":"3","author":"RJ Baldessarini","year":"1996","journal-title":"Am J Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10673229309017072","article-title":"Discontinuation of maintenance treatment in bipolar disorder: risks and implications.","volume":"1","author":"T Suppes","year":"1993","journal-title":"Harv Rev Psychiatry"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1993.01820180046005","article-title":"Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders.","volume":"50","author":"GL Faedda","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000288950","article-title":"Risks and implications of interrupting maintenance psychotropic drug therapy.","volume":"63","author":"RJ Baldessarini","year":"1995","journal-title":"Psychother Psychosom"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4088\/JCP.v57n1001","article-title":"Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders.","volume":"57","author":"RJ Baldessarini","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/appi.ajp.2010.09060880","article-title":"Illness risk following rapid versus gradual discontinuation of antidepressants.","volume":"167","author":"RJ Baldessarini","year":"2010","journal-title":"Am J Psychiatry"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archpsyc.1991.01810360046007","article-title":"Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.","volume":"48","author":"T Suppes","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.164.2.149","article-title":"Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder.","volume":"164","author":"GM Goodwin","year":"1994","journal-title":"Br J Psychiatry"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0269881107085238","article-title":"Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study.","volume":"22","author":"MA Franks","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","article-title":"Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.","volume":"54","author":"AC Viguera","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/archpsyc.55.3.281","article-title":"Medication removal and research in psychotic disorders.","volume":"55","author":"RJ Baldessarini","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.mehy.2010.01.038","article-title":"Treatment-induced stress syndromes.","volume":"74","author":"D Healy","year":"2010","journal-title":"Med Hypotheses"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.161.2.217","article-title":"Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.","volume":"161","author":"JR Geddes","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","article-title":"A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.","volume":"57","author":"CL Bowden","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"ref84","first-page":"693","article-title":"Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study.","volume":"33","author":"CL Bowden","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(71)91331-6","article-title":"Prophylactic lithium in affective disorders. Controlled trial.","volume":"2","author":"A Coppen","year":"1971","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.1973.01750330035006","article-title":"Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group.","volume":"28","author":"RF Prien","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12325-009-0039-0","article-title":"Long-acting risperidone: a review of its role in the treatment of bipolar disorder.","volume":"26","author":"DE Kemp","year":"2009","journal-title":"Adv Ther"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-859X-8-16","article-title":"Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.","volume":"8","author":"KN Fountoulakis","year":"2009","journal-title":"Ann Gen Psychiatry"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/NDT.S3763","article-title":"Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole.","volume":"5","author":"DJ Muzina","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1586\/14737175.7.8.919","article-title":"Maintenance treatment in bipolar disorder: a focus on aripiprazole.","volume":"7","author":"RS McIntyre","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/14656566.8.7.1001","article-title":"Aripiprazole: pharmacology and evidence in bipolar disorder.","volume":"8","author":"RS McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.clinthera.2010.01.022","article-title":"Aripiprazole for the maintenance treatment of bipolar I disorder: a review.","volume":"32","author":"RS McIntyre","year":"2010","journal-title":"Clin Ther"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/14737175.6.12.1777","article-title":"Role of aripiprazole in treating mood disorders.","volume":"6","author":"M Garcia-Amador","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1185\/03007990802341426","article-title":"Practical guidance for prescribing with aripiprazole in bipolar disorder.","volume":"24","author":"A Fagiolini","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref95","first-page":"S27","article-title":"Ikiuclu bozuklukta aripiprazol [Aripiprazole for the treatment of bipolar disorder].","volume":"18","author":"A Ulusahin","year":"2008","journal-title":"Klinik Psikofarmakoloji Bulteni [Bulletin of Clinical Psychopharmacology]"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1399-5618.2009.00672.x","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.","volume":"11","author":"LN Yatham","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Evidence-based guidelines for treating bipolar disorder: revised second edition\u2014recommendations from the British Association for Psychopharmacology.","volume":"23","author":"GM Goodwin","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref98","article-title":"Long-term efficacy of aripiprazole in pediatric patients with bipolar I disorder.","volume":"297","author":"A Forbes","year":"2008","journal-title":"New Research Abstracts; May 3-8 American Psychiatric Association"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archpsyc.57.5.490","article-title":"Maintenance treatment in bipolar disorder.","volume":"57","author":"RJ Baldessarini","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1017\/S0033291706009305","article-title":"What is a mood stabilizer?","volume":"37","author":"GM Goodwin","year":"2007","journal-title":"Psychol Med"},{"key":"ref101","first-page":"103","article-title":"Illness characteristics of patients in clinical drug studies of mania.","volume":"31","author":"CL Bowden","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004714-200202000-00001","article-title":"New designs for studies of the prophylaxis of bipolar disorder.","volume":"22","author":"RM Post","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/archpsyc.1989.01810050076012","article-title":"Outside analysis of a multicenter collaborative study.","volume":"46","author":"RF Prien","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"ref104","first-page":"43","article-title":"Maintenance treatment in bipolar disorder.","volume":"3","author":"M Tohen","year":"2006","journal-title":"Psychiatry (Edgmont)"},{"key":"ref105","first-page":"40","article-title":"Treating bipolar disorder: for the patient or against the illness?","volume":"3","author":"AC Swann","year":"2006","journal-title":"Psychiatry (Edgmont)"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pst.234","article-title":"A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant.","volume":"6","author":"C Mallinckrodt","year":"2007","journal-title":"Pharm Stat"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/j.1552-4604.1975.tb05919.x","article-title":"A clinical trial design avoiding undue placebo treatment.","volume":"15","author":"W Amery","year":"1975","journal-title":"J Clin Pharmacol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0025-7125(16)30685-X","article-title":"Government viewpoint of clinical trials of cardiovascular drugs.","volume":"73","author":"R Temple","year":"1989","journal-title":"Med Clin North Am"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1192\/bjp.164.2.208","article-title":"Lithium prophylaxis of bipolar illness. The value of combination treatment.","volume":"164","author":"ED Peselow","year":"1994","journal-title":"Br J Psychiatry"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/070674370805300309","article-title":"Toward a Hippocratic psychopharmacology.","volume":"53","author":"SN Ghaemi","year":"2008","journal-title":"Can J Psychiatry"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.pra.0000333584.75741.45","article-title":"Gabapentin in the treatment of mental illness: the echo chamber of the case series.","volume":"14","author":"TS Carey","year":"2008","journal-title":"J Psychiatr Pract"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.287.5.612","article-title":"Relationships between authors of clinical practice guidelines and the pharmaceutical industry.","volume":"287","author":"NK Choudhry","year":"2002","journal-title":"JAMA"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM199801083380206","article-title":"Conflict of interest in the debate over calcium-channel antagonists.","volume":"338","author":"HT Stelfox","year":"1998","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3122\/jabfm.18.5.414","article-title":"The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine?","volume":"18","author":"J Abramson","year":"2005","journal-title":"J Am Board Fam Pract"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"e217; discussion e217","DOI":"10.1371\/journal.pmed.0050217","article-title":"Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.","volume":"5","author":"K Rising","year":"2008","journal-title":"PLoS Med"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review.","volume":"326","author":"J Lexchin","year":"2003","journal-title":"BMJ"}],"container-title":["PLoS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1000434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T14:59:58Z","timestamp":1637593198000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1000434"}},"subtitle":[],"editor":[{"given":"Phillipa J.","family":"Hay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,5,3]]},"references-count":116,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1000434","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,3]]}}}